Neurocrine Biosciences Inc. Files Definitive Proxy Statement

Ticker: NBIX · Form: DEF 14A · Filed: 2024-04-10T00:00:00.000Z

Sentiment: neutral

Topics: Proxy Statement, DEF 14A, Neurocrine Biosciences, SEC Filing, Corporate Governance

TL;DR

<b>Neurocrine Biosciences Inc. has filed its Definitive Proxy Statement for the period ending May 22, 2024.</b>

AI Summary

NEUROCRINE BIOSCIENCES INC (NBIX) filed a Proxy Statement (DEF 14A) with the SEC on April 10, 2024. Neurocrine Biosciences Inc. filed a Definitive Proxy Statement (DEF 14A) on April 10, 2024. The filing covers the period ending May 22, 2024. The company's fiscal year ends on December 31. Neurocrine Biosciences Inc. is incorporated in Delaware. The company's principal business is Biological Products (No Diagnostic Substances).

Why It Matters

For investors and stakeholders tracking NEUROCRINE BIOSCIENCES INC, this filing contains several important signals. This DEF 14A filing is a standard regulatory requirement for public companies, providing shareholders with information regarding upcoming meetings and voting matters. The filing details the company's corporate structure, fiscal year-end, and primary business activities, which is crucial for investor understanding and due diligence.

Risk Assessment

Risk Level: low — NEUROCRINE BIOSCIENCES INC shows low risk based on this filing. The filing is a routine DEF 14A, containing standard disclosures and no immediate material events or financial performance data that would indicate high risk.

Analyst Insight

Review the proxy statement for details on executive compensation, board nominations, and any shareholder proposals to understand potential governance changes and management incentives.

Key Numbers

Key Players & Entities

FAQ

When did NEUROCRINE BIOSCIENCES INC file this DEF 14A?

NEUROCRINE BIOSCIENCES INC filed this Proxy Statement (DEF 14A) with the SEC on April 10, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by NEUROCRINE BIOSCIENCES INC (NBIX).

Where can I read the original DEF 14A filing from NEUROCRINE BIOSCIENCES INC?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by NEUROCRINE BIOSCIENCES INC.

What are the key takeaways from NEUROCRINE BIOSCIENCES INC's DEF 14A?

NEUROCRINE BIOSCIENCES INC filed this DEF 14A on April 10, 2024. Key takeaways: Neurocrine Biosciences Inc. filed a Definitive Proxy Statement (DEF 14A) on April 10, 2024.. The filing covers the period ending May 22, 2024.. The company's fiscal year ends on December 31..

Is NEUROCRINE BIOSCIENCES INC a risky investment based on this filing?

Based on this DEF 14A, NEUROCRINE BIOSCIENCES INC presents a relatively low-risk profile. The filing is a routine DEF 14A, containing standard disclosures and no immediate material events or financial performance data that would indicate high risk.

What should investors do after reading NEUROCRINE BIOSCIENCES INC's DEF 14A?

Review the proxy statement for details on executive compensation, board nominations, and any shareholder proposals to understand potential governance changes and management incentives. The overall sentiment from this filing is neutral.

How does NEUROCRINE BIOSCIENCES INC compare to its industry peers?

Neurocrine Biosciences Inc. operates in the biotechnology sector, focusing on the development and commercialization of treatments for neurological and endocrine-related diseases.

Are there regulatory concerns for NEUROCRINE BIOSCIENCES INC?

The filing is a DEF 14A, which is a standard disclosure document required by the SEC under the Securities Exchange Act of 1934.

Industry Context

Neurocrine Biosciences Inc. operates in the biotechnology sector, focusing on the development and commercialization of treatments for neurological and endocrine-related diseases.

Regulatory Implications

The filing is a DEF 14A, which is a standard disclosure document required by the SEC under the Securities Exchange Act of 1934.

What Investors Should Do

  1. Review the proxy statement for details on the annual meeting agenda and voting procedures.
  2. Examine executive compensation packages and any proposed changes to equity incentive plans.
  3. Identify any shareholder proposals and understand the company's stance or recommendations.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a routine disclosure document and does not represent a change from previous filings in terms of its nature, but provides updated information for the current reporting period.

Filing Stats: 4,859 words · 19 min read · ~16 pages · Grade level 12 · Accepted 2024-04-10 16:07:15

Key Financial Figures

Filing Documents

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 5 Compensation Philosophy 45 Our B oard of Directors 7 Overall Compensation Determination Process 45 G eneral 7 Compensation Consultant 46 Director Biographies of Class I Directors Nominated for Reelection at the 2024 Annual Meeting of Stockholder s 7 Competitive Assessment of Compensation—Peer Group and Market Data 47 Director Biographies of Class II and Class III Directors not Nominated for Reelection at the 2024 Annual Meeting of Stockholders 8 Components of Executive Compensation 47 The Board of Directors and Corporate Governance Matters 10 2023 Named Executive Officer Compensation Decisions 50 G eneral 10 Officer Equity Ownership Guidelines 54 C orp orate Governance Best Practices 10 Equity Trading Policies and Procedures 54 Board of Directors Overview 11 Compensation Recoupment Policy 55 Board Leadership Structure 12 Tax and Accounting Considerations 55 Board Independen ce 12 Risk Analysis of Our Compensation Program 55 Classified Board Structure 12 Executive Compensation and Other Information 56 Overboarding Policy 12 Summary Compensation Table 56 Board and Committee Meetings During 2023 13 Grants of Plan-Based Awards During 2023 57 Information About Board Committees 13 Agreements with Named Executive Officers 58 Compensation Committee Interlocks and Insider Participation 14 Outstanding Equity Awards at Fiscal Year-End 59 Director Nomination Process 14 Option Exercises and Stock Vested During the Year 60 Board Diversity Matrix 15 Potential Payments upon Termination or Change-in-Control 60 Board Sel f Assessment 15 CEO Pay Ratio 64 Board Education 15 Item 402(v) Pay Versus Performance 65 Identification and Evaluation of Nominees for Director 15 Director s Compensation Summary 69 Proxy Access 16 Non-Employee Director Compensation Philosophy 69 Process for Stockholder Communications with the Board of Directors 16 Non-Employee Director

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT The following table sets forth certain information regarding the ownership of our common stock as of March 25, 2024 by (i) each director; (ii) each of the executive officers named in the Summary Compensation Table; (iii) our executive officers and directors as a group; and (iv) all those known by us to be beneficial owners of more than five percent of our common stock. Unless otherwise indicated in the footnotes to this table and subject to community property laws where applicable, we believe that each of the stockholders named in this table has sole voting and investment power with respect to the shares indicated as beneficially owned. Applicable percentages are based on 100,580,497 shares of common stock outstanding on March 25, 2024, adjusted as required by rules promulgated by the SEC. The table is based upon information supplied by our executive officers, directors and principal stockholders and a review of Schedules 13D and 13G, if any, filed with the SEC. Unless otherwise indicated below, the address for each beneficial owner listed is c/o Neurocrine Biosciences, Inc., 12780 El Camino Real, San Diego, CA 92130. Name and Address of Beneficial Owner Number of Shares of Common Stock Percent of Common Stock Stockholders Owning Greater than 5%: BlackRock, Inc. (1) 13,647,679 13.6 % The Vanguard Group (2) 9,710,328 9.7 % Directors and Named Executive Officers : Kevin C. Gorman, Ph.D. (3) 1,575,454 1.6 % Matthew C. Abernethy (4) 321,147 * Kyle W. Gano, Ph.D. (5) 577,993 * Jude Onyia, Ph.D. (6) 114,078 * Eiry W. Roberts, M.D. (7) 209,162 * William H. Rastetter, Ph.D. (8) 178,895 * Gary A. Lyons (9) 225,412 * Johanna Mercier (10) 42,127 * George J. Morrow (11) 81,274 * Leslie V. Norwalk (12) 37,965 * Christine A. Poon (13) 4,549 * Richard F. Pops (14) 110,786 * Shalini Sharp (15) 39,947 * Stephen A. Sherwin, M.D. (16) 128,579 * All current executive officers and directors as a g

View on Read The Filing